April 28, 2022 |
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
VBI Vaccines to Participate in Upcoming Investor Conferences
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
